当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2012年第9期
编号:12209562
替比夫定治疗乙型肝炎e抗原阳性慢性乙型肝炎48周疗效观察和安全性评价(3)
http://www.100md.com 2012年3月25日 《中国医药导报》 2012年第9期
     [5]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].中华流行病学杂志,2006,27(1):79-88.

    [6]Bryant ML,Bridges EG,Placidi L,et al. Antiviral L nucleosides specific for hepatitis B virus infection [J]. Antimicrob Agents Chemother,2001,45(1):229-235.

    [7]Lai CL,Rosmawati M,Lao J,et al. Telbivudine is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection [J]. Gastroenterology,2002,123(6):1831-1838.

    [8]Lai CL,Gane E,Hsu CW,et al. Two-year results from the GLOBE Trial in patients with chronic hepatitis B:greater clinical and antiviral efficacy for Telbivudine (LdT) vs Lamivudine[J]. Hepatology,2006,44(suppl 1):222.

    [9]Jia JD,Hou JL,Yin YK,et al. Two-year results of a phase Ⅲ comparative trial of telbivudine vs lamivudine in Chinese patients [J]. Hepatology,2007,46(Suppl 1):189.

    [10]Bzowej N,Chan LYH,Lai CL,et al. A randomized trial of Telbivudine (LdT)vs Adefovir for HBeAg-positive chronic hepatitis B:final week 52 results [J]. Hepatology,2006,44(suppl 1):1005.

    (收稿日期:2011-12-01本文编辑:张瑜杰), http://www.100md.com(方清)
上一页1 2 3